Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1989 1
1990 8
1991 5
1992 6
1993 2
1994 6
1995 11
1996 12
1997 9
1998 6
1999 8
2000 11
2001 8
2002 7
2003 14
2004 10
2005 9
2006 8
2007 13
2008 10
2009 16
2010 12
2011 6
2012 7
2013 18
2014 10
2015 4
2016 6
2017 9
2018 9
2019 4
2020 6
2021 5
2022 3
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
Stromal gene signatures in large-B-cell lymphomas.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Lenz G, et al. Among authors: verhoef g. N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885. N Engl J Med. 2008. PMID: 19038878 Free PMC article.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Among authors: verhoef g. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. O'Brien SG, et al. Among authors: verhoef g. N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457. N Engl J Med. 2003. PMID: 12637609 Free article. Clinical Trial.
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. Among authors: verhoef g. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Physical activity and risk of lymphoma: a meta-analysis.
Vermaete NV, Wolter P, Verhoef GE, Kollen BJ, Kwakkel G, Schepers L, Gosselink R. Vermaete NV, et al. Among authors: verhoef ge. Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1173-84. doi: 10.1158/1055-9965.EPI-13-0182. Epub 2013 May 15. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23677574 Review.
Dicentric (1;15) in myeloid disorders.
Michaux L, Dierlamm J, Mecucci C, Meeus P, Ameye G, Libouton JM, Verhoef G, Ferrant A, Louwagie A, Verellen-Dumoulin C, Van Den Berghe H. Michaux L, et al. Among authors: verhoef g. Cancer Genet Cytogenet. 1996 May;88(1):86-9. doi: 10.1016/0165-4608(95)00218-9. Cancer Genet Cytogenet. 1996. PMID: 8630988 Review.
Two Cases of Heavy Chain MGUS.
Van Keer J, Meijers B, Delforge M, Verhoef G, Poesen K. Van Keer J, et al. Among authors: verhoef g. Case Rep Oncol Med. 2016;2016:8749153. doi: 10.1155/2016/8749153. Epub 2016 Apr 26. Case Rep Oncol Med. 2016. PMID: 27213064 Free PMC article.
257 results